Brokerages Anticipate OraSure Technologies Inc. (OSUR) to Announce $0.08 EPS
Analysts forecast that OraSure Technologies Inc. (NASDAQ:OSUR) will announce earnings of $0.08 per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for OraSure Technologies’ earnings. OraSure Technologies posted earnings of $0.03 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 166.7%. The business is scheduled to issue its next earnings results after the market closes on Wednesday, November 2nd.
On average, analysts expect that OraSure Technologies will report full-year earnings of $0.00 per share for the current financial year. For the next fiscal year, analysts anticipate that the firm will post earnings of $0.00 per share. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow OraSure Technologies.
OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $0.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.05 by $0.02. OraSure Technologies had a net margin of 10.08% and a return on equity of 7.60%. The business earned $31.36 million during the quarter, compared to analysts’ expectations of $31.15 million. During the same quarter in the prior year, the business posted $0.03 earnings per share. OraSure Technologies’s revenue was up 3.2% compared to the same quarter last year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/brokerages-anticipate-orasure-technologies-inc-osur-to-announce-0-08-eps.html
A number of brokerages have commented on OSUR. BTIG Research cut OraSure Technologies from a “buy” rating to a “neutral” rating and set a $8.00 target price for the company. in a report on Monday, September 19th. Jefferies Group reissued a “buy” rating and set a $10.00 target price (up previously from $8.00) on shares of OraSure Technologies in a report on Wednesday, August 31st. TheStreet raised OraSure Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, August 30th. Stephens raised OraSure Technologies from an “equal weight” rating to an “overweight” rating in a report on Monday, August 29th. Finally, Canaccord Genuity increased their target price on OraSure Technologies from $7.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, August 24th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. OraSure Technologies has an average rating of “Buy” and an average target price of $8.58.
OraSure Technologies (NASDAQ:OSUR) traded up 1.7753% during midday trading on Tuesday, reaching $7.8367. 102,807 shares of the company traded hands. OraSure Technologies has a one year low of $4.77 and a one year high of $9.05. The firm has a market capitalization of $435.72 million, a price-to-earnings ratio of 37.3176 and a beta of 1.51. The firm has a 50-day moving average price of $8.30 and a 200-day moving average price of $7.32.
In related news, CEO Douglas A. Michels sold 25,000 shares of the stock in a transaction that occurred on Monday, September 26th. The stock was sold at an average price of $8.22, for a total value of $205,500.00. Following the completion of the transaction, the chief executive officer now directly owns 756,898 shares in the company, valued at $6,221,701.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jack E. Jerrett sold 68,686 shares of the stock in a transaction that occurred on Tuesday, August 30th. The stock was sold at an average price of $8.52, for a total value of $585,204.72. Following the completion of the transaction, the senior vice president now owns 86,441 shares of the company’s stock, valued at $736,477.32. The disclosure for this sale can be found here. 7.80% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Janney Montgomery Scott LLC raised its position in shares of OraSure Technologies by 3.2% in the second quarter. Janney Montgomery Scott LLC now owns 18,824 shares of the company’s stock valued at $121,000 after buying an additional 579 shares during the last quarter. BlackRock Investment Management LLC raised its position in shares of OraSure Technologies by 0.4% in the second quarter. BlackRock Investment Management LLC now owns 215,332 shares of the company’s stock valued at $1,273,000 after buying an additional 942 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of OraSure Technologies by 6.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,387 shares of the company’s stock valued at $327,000 after buying an additional 3,358 shares during the last quarter. State Street Corp raised its position in shares of OraSure Technologies by 0.3% in the second quarter. State Street Corp now owns 1,039,812 shares of the company’s stock valued at $6,145,000 after buying an additional 3,496 shares during the last quarter. Finally, Bogle Investment Management L P DE raised its position in shares of OraSure Technologies by 1.2% in the first quarter. Bogle Investment Management L P DE now owns 397,604 shares of the company’s stock valued at $2,874,000 after buying an additional 4,686 shares during the last quarter. Institutional investors own 79.30% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.